Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1966 1
1970 2
1977 1
1979 1
1980 4
1982 4
1984 2
1985 2
1986 1
1988 1
1998 1
1999 1
2000 6
2001 4
2002 4
2003 4
2004 4
2005 11
2006 8
2007 10
2008 8
2009 10
2010 8
2011 11
2012 16
2013 11
2014 15
2015 13
2016 11
2017 13
2018 18
2019 23
2020 19
2021 16
2022 22
2023 28
2024 18
2025 33

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

336 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, Block GA, Burke S, Castillo FP, Jardine AG, Khawaja Z, Koury MJ, Lewis EF, Lin T, Luo W, Maroni BJ, Matsushita K, McCullough PA, Parfrey PS, Roy-Chaudhury P, Sarnak MJ, Sharma A, Spinowitz B, Tseng C, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Eckardt KU; PRO2TECT Study Group. Chertow GM, et al. N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2035938. N Engl J Med. 2021. PMID: 33913637 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
[Pulmonary metastasectomy].
Dackam S, Ojanguren A, Perentes JY, Abdelnour-Berchtold E, Krueger T, Karenovics W, Triponez F, Gonzalez M. Dackam S, et al. Among authors: krueger t. Rev Med Suisse. 2019 Jun 12;15(655):1221-1225. Rev Med Suisse. 2019. PMID: 31194297 French.
[When to consider lung transplantation?].
Ioakeim F, Mazza T, Casutt A, Balmpouzis Z, Lechartier B, Krueger T, Aubert JD, Berra G, Koutsokera A. Ioakeim F, et al. Among authors: krueger t. Rev Med Suisse. 2022 Nov 16;18(804):2143-2149. doi: 10.53738/REVMED.2022.18.804.2143. Rev Med Suisse. 2022. PMID: 36382974 French.
Surgical Site Infections, Risk Factors, and Outcomes After Liver Transplant.
Schreiber PW, Hoessly LD, Boggian K, Neofytos D, van Delden C, Egli A, Dickenmann M, Hirzel C, Manuel O, Koller M, Rossi S, Banz V, Compagnon P, Dutkowski P, Kremer AE, Berzigotti A, Vionnet J, Goossens N, Semela D, Künzler-Heule P, Bernsmeier C, Kuster SP, Stampf S, Mueller NJ; Swiss Transplant Cohort Study. Schreiber PW, et al. JAMA Netw Open. 2025 Mar 3;8(3):e251333. doi: 10.1001/jamanetworkopen.2025.1333. JAMA Netw Open. 2025. PMID: 40116828 Free PMC article.
Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer.
Zennami K, Graham M, Chikara S, Sysa-Shah P, Rafiqi FH, Wang R, Abel B, Zeng Q, Krueger TEG, Brennen WN, Ganguly S, Zarif JC, Simons B, DeWeese TL, De Marzo A, Yegnasubramanian S, Lupold SE. Zennami K, et al. Among authors: krueger teg. bioRxiv [Preprint]. 2025 May 18:2025.05.14.654101. doi: 10.1101/2025.05.14.654101. bioRxiv. 2025. PMID: 40463282 Free PMC article. Preprint.
Is repeated pulmonary metastasectomy justified?
Forster C, Ojanguren A, Perentes JY, Zellweger M, Federici S, Krueger T, Abdelnour-Berchtold E, Gonzalez M. Forster C, et al. Among authors: krueger t. Clin Exp Metastasis. 2020 Dec;37(6):675-682. doi: 10.1007/s10585-020-10056-w. Epub 2020 Sep 13. Clin Exp Metastasis. 2020. PMID: 32920725 Free PMC article.
336 results